Compare ALEMBIC with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs STRIDES PHARMA SCIENCE - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC STRIDES PHARMA SCIENCE ALEMBIC/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 60.5 23.1 262.2% View Chart
P/BV x 5.2 2.2 241.1% View Chart
Dividend Yield % 0.2 0.2 87.1%  

Financials

 ALEMBIC   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ALEMBIC
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
ALEMBIC/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs721,147 6.3%   
Low Rs34642 5.3%   
Sales per share (Unadj.) Rs4.7317.2 1.5%  
Earnings per share (Unadj.) Rs6.17.8 77.8%  
Cash flow per share (Unadj.) Rs6.225.1 24.9%  
Dividends per share (Unadj.) Rs0.202.00 10.0%  
Dividend yield (eoy) %0.40.2 168.9%  
Book value per share (Unadj.) Rs40.7274.3 14.8%  
Shares outstanding (eoy) m267.0389.50 298.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x11.32.8 399.5%   
Avg P/E ratio x8.7114.0 7.6%  
P/CF ratio (eoy) x8.535.7 23.7%  
Price / Book Value ratio x1.33.3 39.9%  
Dividend payout %3.325.5 12.9%   
Avg Mkt Cap Rs m14,13980,058 17.7%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m2074,341 4.8%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m1,25528,394 4.4%  
Other income Rs m370941 39.4%   
Total revenues Rs m1,62529,334 5.5%   
Gross profit Rs m1113,965 2.8%  
Depreciation Rs m381,540 2.5%   
Interest Rs m21,962 0.1%   
Profit before tax Rs m4421,403 31.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,212-168 -721.4%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m2497 24.6%   
Profit after tax Rs m1,630702 232.1%  
Gross profit margin %8.914.0 63.4%  
Effective tax rate %5.46.9 78.2%   
Net profit margin %129.82.5 5,251.2%  
BALANCE SHEET DATA
Current assets Rs m1,86724,836 7.5%   
Current liabilities Rs m59118,993 3.1%   
Net working cap to sales %101.620.6 494.0%  
Current ratio x3.21.3 241.5%  
Inventory Days Days9471 132.8%  
Debtors Days Days74113 64.8%  
Net fixed assets Rs m1,79134,289 5.2%   
Share capital Rs m534895 59.7%   
"Free" reserves Rs m10,32423,651 43.7%   
Net worth Rs m10,85824,546 44.2%   
Long term debt Rs m4115,513 0.3%   
Total assets Rs m11,59165,437 17.7%  
Interest coverage x260.91.7 15,211.4%   
Debt to equity ratio x00.6 0.6%  
Sales to assets ratio x0.10.4 25.0%   
Return on assets %14.14.1 345.7%  
Return on equity %15.02.9 524.8%  
Return on capital %15.26.9 220.3%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1915,697 0.1%   
Fx outflow Rs m264735 35.9%   
Net fx Rs m-24414,962 -1.6%   
CASH FLOW
From Operations Rs m2361,871 12.6%  
From Investments Rs m-2245,826 -3.8%  
From Financial Activity Rs m-27-10,157 0.3%  
Net Cashflow Rs m-15-2,615 0.6%  

Share Holding

Indian Promoters % 64.0 27.7 231.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 37.8 0.5%  
FIIs % 9.7 8.6 112.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 25.9 100.8%  
Shareholders   54,701 56,241 97.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   SUVEN LIFE SCIENCES  NEULAND LABS  PIRAMAL ENTERPRISES  FDC  SUN PHARMA  

Compare ALEMBIC With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Dow Futures Up by 6 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 20, 2021 03:24 PM

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - JUBILANT LIFE SCIENCES COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS